Mersana Therapeutics Implements Strategic Restructuring And Reprioritization Plan To Extend Cash Runway, Advance Emi-Le; XMT-1660

Benzinga · 05/06/2025 11:09
  • Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026
  • Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC.